The FDA has approved Novo Nordisk’s PrandiMet, a combination of the insulin secretagogue repaglinide and metformin for the treatment of type 2 diabetes.
Pasteur, the vaccines division of the Sanofi-Aventis Group, announced that the FDA has licensed Pentacel, a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use in infants and children 6 weeks through 4 years of age (prior to age 5).
